Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sweeney

Showing results (711-720 of 762) with videos related to

Pageof 77
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Epilepsia|March 16, 2024
Somatic variants as a cause of drug-resistant epilepsy including mesial temporal lobe epilepsy with hippocampal sclerosisRobert J Carton, Michael G Doyle, Hugh Kearney, et al.
The Journal of Clinical Investigation|November 19, 2024
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in miceKatherine L Morel, Beatriz Germán, Anis A Hamid, et al.
The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
Annals of the New York Academy of Sciences|April 27, 2007
Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER studyS Trompet, D Pons, A J M DE Craen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Light, Science & Applications|January 11, 2026
Mid-infrared InAs/InP quantum-dot lasersYangqian Wang, Hui Jia, Jae-Seong Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Journal of the American Geriatrics Society|November 6, 2007
Association between apolipoprotein E4 and cognitive decline in elderly adultsChris J Packard, Rudi G J Westendorp, David J Stott, et al.
Pageof 77

Showing results (711-720 of 762) with videos related to

Sort By:
Pageof 77
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Epilepsia|March 16, 2024
Somatic variants as a cause of drug-resistant epilepsy including mesial temporal lobe epilepsy with hippocampal sclerosisRobert J Carton, Michael G Doyle, Hugh Kearney, et al.
The Journal of Clinical Investigation|November 19, 2024
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in miceKatherine L Morel, Beatriz Germán, Anis A Hamid, et al.
The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
Annals of the New York Academy of Sciences|April 27, 2007
Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER studyS Trompet, D Pons, A J M DE Craen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Light, Science & Applications|January 11, 2026
Mid-infrared InAs/InP quantum-dot lasersYangqian Wang, Hui Jia, Jae-Seong Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Journal of the American Geriatrics Society|November 6, 2007
Association between apolipoprotein E4 and cognitive decline in elderly adultsChris J Packard, Rudi G J Westendorp, David J Stott, et al.
Pageof 77